Medications

Antibody eradicates leukemia stem cells

The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80 percent of people with CML who received the drug, the disease went into complete ...

Oncology & Cancer

At molecular level, cancer mutations echo Darwin's observations

There are more than 100 mutations of the protein behind the deadly brain cancer, glioblastoma, however an international research team has discovered something these mutations have in common. The new understanding could lead ...

Oncology & Cancer

Reasons for TKI discontinuation ID'd in chronic myeloid leukemia

(HealthDay)—For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online ...

Oncology & Cancer

Ibrance approval expanded to include men with breast cancer

(HealthDay)—U.S. Food and Drug Administration approval of Ibrance (palbociclib) capsules has been widened to include men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic ...

Oncology & Cancer

Tobacco use makes precancerous cells that fertilize cancer growth

Tobacco use causes a field of precancerous cells, increasing the risk of developing head & neck cancer. But exactly how this precancerous field influences cancer has been often overlooked. Now a University of Colorado Cancer ...

Oncology & Cancer

Tarloxotinib promising against NRG1-fusion cancers

A study by University of Colorado Cancer Center and Rain Therapeutics, Inc. presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 shows that the clinical-stage drug, tarloxotinib, is active ...

page 1 from 18